Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments - Seite 2
Andrew Farnum, CEO at Variant Bio, said: "Evotec has established and validated in vitro and in vivo models to accelerate programme timelines and is ideally positioned to advance our fibrosis programme. They have the experience and track record in converting breakthrough science into medicines that matter for patients."
Dr David Moller, CSO at Variant Bio, added: "We are thrilled to collaborate with Evotec given their deep expertise in disease biology and their outstanding drug discovery capabilities that complement Variant Bio's R&D team. These factors will play a critical role in the success of our pre-clinical and development goals."
ABOUT VARIANT BIO
Variant Bio is developing life-saving therapies by studying the genes of people with exceptional health-related traits. By identifying communities with unique genetic architectures and outlier
phenotypes, Variant Bio has identified novel human genetic evidence that is the basis for programs with breakthrough potential across multiple therapeutic areas. The company's research is powered
by its proprietary VB-Inference platform, which integrates deep phenotyping and multi-omics data using statistical genetics and AI/ML approaches to identify and validate therapeutic targets. With
ethics at its core, the company launched an unprecedented benefit-sharing program in 2020, in which it has pledged tangible benefits that directly impact the communities it partners with throughout
the world. Variant Bio is now poised to advance multiple potentially life-changing therapeutic programs toward the clinic, and to create concomitant value for partner communities who have entrusted
the company with their genetic data. Follow Variant Bio's news and updates at www.variantbio.com and via its
blog , on X/Twitter @VariantBio, on
Instagram @variant_bio, and on LinkedIn.
Variant Bio Contacts
Sarah LeBaron von Baeyer, Director of Ethics and Engagement sarah@variantbio.com, www.variantbio.com
Lesen Sie auch
ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The
Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class
pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800
biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g.
neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has
to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly
qualified people. The Company's 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec
and LinkedIn.